An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites

Oncotarget

Volumn 6, Issue 2, 2015, Pages 902-914

  Fu, Xinping ^a   Rivera, Armando ^a   Tao, Lihua ^a   Zhang, Xiaoliu ^a  

^a University of Houston   (United States)

Author keywords

Adoptive T cell transfer; Antitumor immunity; Chemokines; Oncolytic virus; T cell migration

Indexed keywords

CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; ONCOLYTIC HERPES VIRUS; CHEMOKINE; CHEMOKINE RECEPTOR; IL2RG PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR GAMMA; ONCOLYTIC VIRUS;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EFFECTOR CELL; EX VIVO STUDY; HERPES SIMPLEX VIRUS 2; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE MIGRATION; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS ADENOCARCINOMA; SPLEEN CELL; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; C57BL MOUSE; CELL LINE; CELL MOTION; CHLOROCEBUS AETHIOPS; DEFICIENCY; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASMS, EXPERIMENTAL; NONOBESE DIABETIC MOUSE; PHYSIOLOGY; PROCEDURES; SCID MOUSE; TRANSGENIC MOUSE; TRANSPLANTATION; TUMOR CELL LINE; TUMOR VOLUME; VERO CELL LINE; VIROLOGY;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CERCOPITHECUS AETHIOPS; CHEMOKINES; COMBINED MODALITY THERAPY; HERPESVIRUS 2, HUMAN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES; TUMOR BURDEN; VERO CELLS;

EID: 84921788244     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2817     Document Type: Article

References (45)

1. Kalos M and June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 2013; 39(1):49-60.
2. Vitale M, Pelusi G, Taroni B, Gobbi G, Micheloni C, Rezzani R, Donato F, Wang X and Ferrone S. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res. 2005; 11(1):67-72.
3. Davies DM and Maher J. Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells. Arch Immunol Ther Exp (Warsz). 2010; 58(3):165-178.
4. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29(7):917-924.
5. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA and Rosenberg SA. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010; 116(20):4099-4102.
6. Porter DL, Levine BL, Kalos M, Bagg A and June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-733.
7. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL and June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16):1509-1518.
8. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE and Brenner MK. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008; 14(11):1264-1270.
9. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011; 19(3):620-626.
10. Gajewski TF, Fuertes M, Spaapen R, Zheng Y and Kline J. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol. 2011; 23(2):286-292.
11. Nakanishi Y, Lu B, Gerard C and Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature. 2009; 462(7272):510-513.
12. Kim CH, Rott L, Kunkel EJ, Genovese MC, Andrew DP, Wu L and Butcher EC. Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest. 2001; 108(9):1331-1339.
13. Shin H and Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature. 2012; 491(7424):463-467.
14. Fu X, Tao L, Cai R, Prigge J and Zhang X. A Mutant Type 2 Herpes Simplex Virus Deleted for the Protein Kinase Domain of the ICP10 Gene Is a Potent Oncolytic Virus. Mol Ther. 2006; 13(5):882-890.
15. Fu X, Tao L, Li M, Fisher WE and Zhang X. Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus. Clin Cancer Res. 2006; 12(10):3152-3157.
16. Fu X, Tao L and Zhang X. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer. Cancer Gene Ther. 2007; 14(5):480-487.
17. Li H, Dutuor A, Fu X and Zhang X. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model. J Gene Med. 2007; 9(3):161-169.
18. Li H, Dutuor A, Tao L, Fu X and Zhang X. Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin Cancer Res. 2007; 13(1):316-322.
19. Li H, Zeng Z, Fu X and Zhang X. Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses. Cancer Res. 2007; 67(16):7850-7855.
20. Clarke SR, Barnden M, Kurts C, Carbone FR, Miller JF and Heath WR. Characterization of the ovalbumin-specific TCR transgenic line OT-I: MHC elements for positive and negative selection. Immunology and cell biology. 2000; 78(2):110-117.
21. Wang B, Shi Q, Abbruzzese J, Xiong Q, Le X and Xie K. A Novel, Clinically Relevant Animal Model of Metastatic Pancreatic Adenocarcinoma Biology and Therapy. Int J Gastrointest Cancer. 2001; 29(1):37-46.
22. Nakamori M, Fu X, Rousseau R, Chen SY and Zhang X. Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Mol Ther. 2004; 9(5):658-665.
23. Sallusto F, Lenig D, Forster R, Lipp M and Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999; 401(6754):708-712.
24. Campanella GS, Medoff BD, Manice LA, Colvin RA and Luster AD. Development of a novel chemokine-mediated in vivo T cell recruitment assay. J Immunol Methods. 2008; 331(1-2):127-139.
25. Groom JR and Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunology and cell biology. 2011; 89(2):207-215.
26. Ebert LM, Schaerli P and Moser B. Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Molecular immunology. 2005; 42(7):799-809.
27. Moser B. Chemokines: role in immune cell traffic. European cytokine network. 2003; 14(4):204-210.
28. Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, Whittington M, Yang Y, Overwijk WW, Lizee G and Hwu P. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res. 2010; 16(22):5458-5468.
29. Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Powell DJ, Jr., Riley JL, June CH and Albelda SM. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011; 17(14):4719-4730.
30. Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop HE, Brenner MK, Dotti G and Savoldo B. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009; 113(25):6392-6402.
31. Li J, O'Malley M, Sampath P, Kalinski P, Bartlett DL and Thorne SH. Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity. Neoplasia. 2012; 14(12):1115-1121.
32. Li J, O'Malley M, Urban J, Sampath P, Guo ZS, Kalinski P, Thorne SH and Bartlett DL. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther. 2011; 19(4):650-657.
33. Zlotnik A and Yoshie O. The chemokine superfamily revisited. Immunity. 2012; 36(5):705-716.
34. Benencia F, Courreges MC, Conejo-Garcia JR, Mohamed-Hadley A, Zhang L, Buckanovich RJ, Carroll R, Fraser N and Coukos G. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther. 2005; 12(5):789-802.
35. Loetscher P, Seitz M, Baggiolini M and Moser B. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J Exp Med. 1996; 184(2):569-577.
36. Sozzani S, Luini W, Borsatti A, Polentarutti N, Zhou D, Piemonti L, D'Amico G, Power CA, Wells TN, Gobbi M, Allavena P and Mantovani A. Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J Immunol. 1997; 159(4):1993-2000.
37. Kernacki KA, Barrett RP, McClellan S and Hazlett LD. MIP-1alpha regulates CD4+ T cell chemotaxis and indirectly enhances PMN persistence in Pseudomonas aeruginosa corneal infection. Journal of leukocyte biology. 2001; 70(6):911-919.
38. Carr MW, Roth SJ, Luther E, Rose SS and Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA. 1994; 91(9):3652-3656.
39. Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C and Germain RN. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature. 2006; 440(7086):890-895.
40. Diaz RM, Galivo F, Kottke T, Wongthida P, Qiao J, Thompson J, Valdes M, Barber G and Vile RG. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res. 2007; 67(6):2840-2848.
41. Toda M, Rabkin SD, Kojima H and Martuza RL. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther. 1999; 10(3):385-393.
42. Ito H, Aoki H, Kuhnel F, Kondo Y, Kubicka S, Wirth T, Iwado E, Iwamaru A, Fujiwara K, Hess KR, Lang FF, Sawaya R and Kondo S. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst. 2006; 98(9):625-636.
43. Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, Peach H, Phillips RM, Bond J, Pandha H, Harrington K, Vile R, Russell S, Selby P and Melcher AA. Measles virus causes immunogenic cell death in human melanoma. Gene Ther. 2013; 20(1):7-15.
44. Thorne SH. Immunotherapeutic potential of oncolytic vaccinia virus. Immunologic research. 2011; 50(2-3):286-293.
45. Li QX, Liu G and Zhang X. Fusogenic Oncolytic Herpes Simplex Viruses as a Potent and Personalized Cancer Vaccine. Curr Pharm Biotechnol. 2011.